PITTSBURGH, Jan. 20, 2015 /PRNewswire/ -- Mylan Inc.
(Nasdaq: MYL) today announced that the U.S. Supreme Court has
partially modified the standard of review to be applied by the U.S.
Court of Appeals for the Federal Circuit when reviewing a lower
court's evidentiary findings made when construing a patent
claim. Additionally, the Supreme Court has remanded the case
relating to Teva's U.S. Patent No. 5,800,808 ("the '808 patent") to
the Federal Circuit for that court to review the patent's validity
in accordance with the modified standard of review. The '808 patent
expires on Sept. 1, 2015.
Mylan CEO Heather Bresch said,
"We continue to believe that the '808 patent is invalid as
indefinite and we will address that issue with the Federal Circuit
Court of Appeals. Nevertheless, Mylan's global platform has
consistently demonstrated that our success is not about any one
product. With that said, we look forward to bringing our
generic version of Copaxone® to market."
Private Securities Litigation Reform Act of 1995 — A Caution
Concerning Forward-Looking Statements
This press release includes statements that constitute
"forward-looking statements," including with regard to litigation
and sales of products. These statements are made pursuant to the
safe harbor provisions of the Private Securities Litigation Reform
Act of 1995. Because such statements inherently involve risks and
uncertainties, actual future results may differ materially from
those expressed or implied by such forward-looking statements.
Factors that could cause or contribute to such differences include,
but are not limited to: strategies by competitors or other third
parties to delay or prevent product introductions; risks inherent
in legal and regulatory processes; uncertainties and other matters
beyond the control of management; and the other risks detailed in
the company's filings with the Securities and Exchange Commission.
The company undertakes no obligation to update these statements for
revisions or changes after the date of this release.
Mylan is a global pharmaceutical company committed to setting
new standards in health care. Working together around the world to
provide 7 billion people access to high quality medicine, we
innovate to satisfy unmet needs; make reliability and service
excellence a habit; do what's right, not what's easy; and impact
the future through passionate global leadership. We offer a growing
portfolio of more than 1,300 generic pharmaceuticals and several
brand medications. In addition, we offer a wide range of
antiretroviral therapies, upon which approximately 40% of HIV/AIDS
patients in developing countries depend. We also operate one of the
largest active pharmaceutical ingredient manufacturers and
currently market products in approximately 140 countries and
territories. Our workforce of more than 25,000 people is dedicated
to improving the customer experience and increasing pharmaceutical
access to consumers around the world. Learn more at mylan.com.
Logo - http://photos.prnewswire.com/prnh/20140423/77793
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/us-supreme-court-partially-modifies-standard-of-review-of-patent-claim-construction-and-remands-review-of-tevas-808-patent-on-copaxone-to-federal-circuit-court-of-appeals-300022984.html
SOURCE Mylan Inc.